Inflammatix is developing immune response diagnostics to identify the presence of bacterial and viral infections. Biomarkers in blood can reveal if a patient is mounting an immune response to a pathogen, including infections that haven’t spread to the bloodstream yet and are often missed using pathogen-focused diagnostic methods. Inflammatix is creating point-of-care instruments that provide an accurate diagnostic for acute infections within 30 minutes by focusing on the immune response. The instruments in development, TriVerity for hospitals and BacVerity for clinics, are designed to identify the presence, type and severity of acute infections. This is important to ensure that smarter antibiotics are prescribed to patients to improve success and reduce the likelihood of antimicrobial resistance.

<p>Inflammatix is developing immune response diagnostics to identify the presence of bacterial and viral infections. Biomarkers in blood can reveal if a patient is mounting an immune response to a pathogen, including infections that haven’t spread to the bloodstream yet and are often missed using pathogen-focused diagnostic methods. Inflammatix is creating point-of-care instruments that provide an accurate diagnostic for acute infections within 30 minutes by focusing on the immune response. The instruments in development, TriVerity for hospitals and BacVerity for clinics, are designed to identify the presence, type and severity of acute infections. This is important to ensure that smarter antibiotics are prescribed to patients to improve success and reduce the likelihood of antimicrobial resistance.</p>


Inflammatix

Medical Device Manufacturing Technician

Controller

Manager Cost Accounting 

Inflammatix Ships TriVerity™ Test Cartridges and Myrna™ Instruments to the U.S. Military - PR Newswire

Inflammatix Completes Development for Acute Infection and Sepsis Test System - Global Biodefense

 Valley Fever: An Invisible Killer Expands Its Range in the ... 

Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up - 360Dx

Inflammatix Named a Finalist in Fast Company's 2018 World Changing Ideas Awards for Its Novel HostDx Tests - PR Newswire

It was great to meet so many healthcare innovators at the Institute for Healthcare Improvement while in Orlando for the IHI Forum 2024. There was a clear fit and excitement for the benefits the TriVerity™ Test System can offer healthcare systems ready to adopt innovation.  

Here's Mike Robinson on the left with Chad Brueck at our booth! 

The TriVerity Test is not for sale and does not have marketing approval or clearance from regulatory authorities in any jurisdiction.

#diagnostics #innovation #sepsis #hostresponse  

Inflammatix Initiates TriVerity™ for Improved Management of Emergency Department Patients with Suspected Infections (TIMED) Trial - PR Newswire

Medtronic’s chief medical officer of acute care and monitoring departs for new role - MedTech Dive

 Inflammatix Gets FDA Clearance for 30-Minute Sepsis Test, Preps for US Launch 


                    Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsis
                


              Eusem - PRESS RELEASE: Half of all patients with sepsis die within two years
            

Join #TeamInflammatix Wednesday, April 16th [register here: https://lnkd.in/geQXXucs] for an in-depth webinar on the TriVerity™ Test System, led by Chief Medical Officer Sam Ajizian MD.

Dr. Ajizian will cover:

- An overview of the TriVerity™ Test System and Myrna Instrument
- The impact of rapid sepsis detection on both hospitals and patients
- Case studies and expert insights delving into the needs met by advanced diagnostics

Can’t attend Wednesday? We’re offering a second session on Thursday, April 17th. Register here: https://lnkd.in/geQXXucs

#EmergencyMedicine #HealthcareInnovation #Diagnostics #Sepsis #HealthcareWebinar

Offering quick way for ERs to treat a deadly condition, South Bay company scores FDA OK - The Business Journals

Targeting FDA OK for its test against deadly sepsis, South Bay company raises $57 million - The Business Journals

VISIT HOSTRESPONSEDX.COM

 Systems and methods for deriving and optimizing classifiers from multiple … 


							  
							     
							  
							  Validity of a blood-based 3-gene signature score for progression and diagnosis of tuberculosis, disease severity and tx response Warsinke HC, et al. JAMA. Oct 2018. 
							  

Drug & Device Development 

www.inflammatix.com


							  
							     
							  
							  A Multi-mRNA Prognostic Signature for Anti-TNFα Therapy Response in Patients with Inflammatory Bowel Disease Sakaram, S. et.al. Diagnostics. Oct 2021. 
							  

Inflammatix nets $102M to advance its immune system ...

Inflammatix sepsis test scores FDA breakthrough device designation - BioWorld Online

Inflammatix Receives FDA Clearance for First-in-Class TriVerity™ Test - PR Newswire

 Inflammatix Appoints Purvesh Khatri as Chief Scientific Officer 


							  
							     
							  
							  Rapid and accurate diagnosis and prognosis of acute infections and sepsis from whole blood using host response mRNA amplification and result interpretation by machine-learning classifiers Liesenfeld, O. et al. Research Square. Oct 2024. Pre-Print. 
							  

 DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic That Predicts COVID-19 Severity Risk 


                    Inflammatix sepsis test scores FDA breakthrough device designation
                


							  
							     
							  
							  A standardized protocol using clinical adjudication to define true infection status in patients presenting to the emergency department with suspected infections and/or sepsis Whitfield, N. et al. DMID. May 2024. 
							  

 Fluidic device and methods for characterization of an infection or other … 

SUBSPACE Consortium

Do Your Genes Know What’s Making You Sick? - The Atlantic

 Methods for diagnosing myocardial infarction 

As hard as it is to believe that we’re already approaching a new year, we’re excited to ring in 2025. Happy New Year! 

FDA clears sepsis test that significantly reduces life-or-death diagnosis time - Stanford Report

 Inflammatix Appoints Amy Boyle as Chief Operating Officer 

We are grateful to have had the inspiring Kristan Seaford speak to our team about her experience with #sepsis. A life-changing event that resulted in multiple amputations, Kristan persevered with the support of her family and friends and by embracing her faith.

In fact, Kristan did more than persevere; she thrived, raising five children, supporting the amputee community as a certified peer visitor, and serving as a mental health counselor. She now inspires others to achieve their goals by sharing her story of resilience and hope. #SepsisAlliance #SepsisAwareness

Read about her story here https://lnkd.in/euPE6cpp

 Inflammatix raises $102M 

Inflammatix Announces Funding from BARDA to Advance HostDx™ Tests - PR Newswire

As #LabWeek draws to a close, we want to spotlight one of the awesome laboratory directors that we’re privileged to work with, Stephen Gombos! As the Director of Laboratory Services at Licking Memorial Health Systems, Stephen works closely with the lab team to quickly and effectively diagnose acute infections, leading to early intervention and improved patient outcomes.

“Watching individuals in the lab grow and develop into leaders in the field is one of the most rewarding parts of my job,” said Stephen. “Mentoring and supporting my team members as they advance in their careers not only strengthens our lab but also contributes to the broader medical community.”

Thank you, Stephen, for all that you and your team do!

#LabWeek2025 #TheLabIsEverything #MedicalDiagnostics #PatientCare #Diagnostics #Microbiology #HostResponse #InfectiousDisease #Pathology #EmergencyMedicine


							  
							     
							  
							  Gene expression–based diagnosis of infections in critically ill patients: Validation of the SepsisMetaScore Thair, S. et al. Critical Care Medicine. April 2021. 
							  


                    Inflammatix Adds MedTech Veteran as First General Counsel
                


                    Inflammatix Raises $57M in Series E Financing
                


              Join our Cloud HD Video Meeting
            

We had a great time connecting with microbiology and infectious diseases leaders at #ESCMIDGlobal! Our Senior Director of Medical Affairs Natalie N. Whitfield, Ph.D., D(ABMM) presented the latest data on our molecular host response test for the diagnosis of acute infections and prognosis of sepsis — the science and unique capability behind #TriVerity.

Thank you to ESCMID - European Society of Clinical Microbiology and Infectious Diseases for hosting such a thought-provoking, connective event.

#ESCMID #SepsisCare #EmergencyMedicine #Diagnostics #InfectiousDisease


							  
							     
							  
							  The optimization and biological significance of a 29-host-immune-mRNA panel for the diagnosis of acute infections and sepsis He, Y. et al. J. Pers. Med. June 2021. 
							  

EXPLORE THE FAIRNESS IN DIAGNOSTICS STUDY

Inflammatix gets $32M infusion for HostDx rapid POC tests - LabPulse

Inflammatix collects $57M as it awaits FDA review of ...

Inflammatix Checks off All the Right Boxes with Investors - Medical Device and Diagnostic industry


							  
							     
							  
							  A transcriptomic severity classifier IMX-SEV-3b to predict mortality in ICU patients with COVID-19 Daenen, K. et al. J. Clin. Med. Sep 2023. 
							  

 Inflammatix Announces $57M Series E Round 


							  
							     
							  
							  A machine learning classifier using 33 host immune response mRNAs accurately distinguishes viral and non-viral acute respiratory illnesses in nasal swab samples Pandya, R. et al. Genome Medicine. Aug 2023. 
							  

Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics - Business Wire


							  
							     
							  
							  Pilot study of a novel serum mRNA gene panel for diagnosis of acute septic arthritis Sweeney TE, Schultz B, et al. World Journal of Orthopedics. Dec 2019. 
							  


                    Inflammatix Completes Technical Development for TriVerity™ Acute Infection and Sepsis Test System
                


							  
							     
							  
							  A 29-mRNA host-response classifier identifies bacterial infections following liver transplantation – a pilot study Halder, A. et al.Langenbecks Arch Surg. Jun 2024. 
							  


							  
							     
							  
							  International multi-cohort analysis identifies novel framework for quantifying immune dysregulation in critical illness: results of the SUBSPACE consortium Moore, A. et al. bioRxiv. Nov 2024. Pre-Print. 
							  

Inflammatix Completes Technical Development for TriVerity™ Acute Infection and Sepsis Test System - PR Newswire

Inflammatix Presents Data at ACEP24 Showing High Diagnostic and Prognostic Accuracy of its TriVerity™ Test Regardless of Patient Immune Status - PR Newswire

We are proud to announce Purvesh Khatri’s presentation at the 16th Genomic Medicine Meeting - Host Genomics and Infectious Disease: Opportunities for Implementing Genomic Medicine [Dec. 12-13], hosted by the National Human Genome Research Institute (NHGRI) and National Institute of Allergy and Infectious Diseases (NIAID)! 

Meeting info: https://lnkd.in/ezqYfYUn

Our team will discuss how host-response diagnostics can advance precision healthcare.

#GenomicMedicine #diagnostics #innovation

Our rockstar Senior Director of Medical Affairs Natalie N. Whitfield, Ph.D.,  is heading to ESCMID - European Society of Clinical Microbiology and Infectious Diseases to represent #TeamInflammatix and educate peers about #TriVerity! We’re looking forward to connecting with microbiology leaders and sharing our latest research on molecular host response tests for the diagnosis of acute infections and prognosis of sepsis. Stop by Hall 11 at 11am on April 14th to hear Natalie present new data about our work, specifically how the TriVerity Test compares to a protein-based host response test for the diagnosis of bacterial and viral infections.

#SepsisCare #EmergencyMedicine #EmergencyMed #Diagnostics #InfectiousDisease #ESCMID #ESCMIDGlobal

BARDA backs Inflammatix test to improve antibiotic use - MedTech Dive

 Stanford Spinout Inflammatix Developing Sepsis Diagnostic Based on Host Immune Response 

 Inflammatix Adds Three MedTech Industry Veterans to Executive Leadership Team 


							  
							     
							  
							  Inflammatory macrophage-associated 3-gene signature predicts subclinical allograft injury and graft survival Azad TD, et al. Journal of Clinical Investigation. Jan 2018. 
							  


                    A better, faster sepsis test that can save lives
                


                    Inflammatix begins trial evaluating mRNA test for patient infection status
                

Inflammatix Gets FDA Clearance for 30-Minute Sepsis Test, Preps for US Launch - 360Dx


							  
							     
							  
							  A community approach to mortality prediction in sepsis via gene expression analysis Sweeney TE, et al. Nature Communications. Feb 2018. 
							  

Attending #AAEM25? Join #TeamInflammatix on April 8th at our New Technology Luncheon! CEO Tim Sweeney, MD, PHD and CMO Sam Ajizian MD, will lead a deep dive into TriVerity™, the only FDA-cleared blood test as an aid in the diagnosis of acute infection and prognosis for sepsis.

Space is limited, so the event is first-come, first-serve. See you there!

#EmergencyMedicine #HealthcareInnovation #Diagnostics #Sepsis

Inflammatix begins trial evaluating mRNA test for patient infection status - Clinical Trials Arena

Inflammatix Announces Additional $12.1 Million Funding From BARDA for ViraBac EZ Acute Infection Test - Business Wire


                    Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test
                

Inflammatix collects FDA clearance for ER sepsis ...

Inflammatix concludes acute infection and sepsis test system development - Medical Device Network

 Exagen Settles With DOJ on Kickback Allegations 

 Isothermal amplification-based diagnosis and treatment of acute infection 

Inflammatix nabs $102M in series D financing for host response diagnostics - BioWorld Online


                    Inflammatix Gets FDA Clearance for 30-Minute Sepsis Test, Preps for US Launch
                


							  
							     
							  
							  Detection of viral infection and bacterial co- and superinfection in COVID-19 patients presenting to the emergency department using the 29-mRNA host response classifier BVN-3 – a multicenter study Bauer, W. et al. Open Forum Infectious Diseases. Aug 2022. 
							  

Inflammatix Scores FDA Approval for Precision Infection Test - Inside Precision Medicine

 >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 


                    Do Your Genes Know What’s Making You Sick?
                

 Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics 


							  
							     
							  
							  Multisite validation of a host response signature for predicting likelihood of bacterial and viral infections in patients with suspected influenza Shojaei, M. et al. Eur J Clin Invest. Jan 2023. 
							  


							  
							     
							  
							  Diagnosis of bacterial sepsis: Why are tests for bacteremia not sufficient? Sweeney TE, Liesenfeld O. Expert Review of Molecular Diagnostics. Aug 2019. 
							  

Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test - Business Wire


                TriVerity - Inflammatix
              


							  
							     
							  
							  A novel 29-messenger RNA host-response assay from whole blood accurately identifies bacterial and viral infections in the ED Bauer, W. et al. Critical Care Medicine. June 2021. 
							  


                    Artificial Intelligence for Clinical Decision Support in Sepsis
                

How a young Peninsula company snagged a onetime Roche exec to battle sepsis - The Business Journals


							  
							     
							  
							  Sepsis subclasses: A framework for development and interpretation DeMerle, K. et al. Critical Care Medicine. Feb 2021. 
							  


							  
							     
							  
							  Transcriptomic similarities and differences in host response between SARS-CoV-2 and other viral infections Thair, S. et al. iScience. Dec 2020. 
							  


							  
							     
							  
							  Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters Sweeney, TE, et al. Critical Care Medicine. Mar 2018. 
							  

Inflammatix Adds Three MedTech Industry Veterans to Executive Leadership Team - StreetInsider


                    Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up
                

 Virology Specimen Collection Industry Gains Momentum on its ... 

 Inflammatix raises $32M, plus a BARDA contract, for its point-of-care infection diagnostics 


							  
							     
							  
							  Outcomes of metabolic resuscitation early treatment of sepsis (ORANGES) trial Iglesias, J. et al. J. Pers. Med. Dec 2020. 
							  

That's a wrap on #AAEM2025! #TeamInflammatix proudly presented our latest advancements in host-response diagnostics, highlighting our commitment to transforming acute infection and sepsis care. We’re grateful for the opportunity to connect with leaders in emergency medicine and share our vision for faster, more accurate diagnostics.

Thanks to American Academy of Emergency Medicine (AAEM) and all those in attendance for facilitating such a great event.

#Triverity #Inflammatix #SepsisCare #EmergencyMedicine #EmergencyMed #IVD #Diagnostics #HealthcareTransformation #AAEM

Inflammatix

Business:

About: